How are energy investors positioned?
NEW YORK/SANTA BARBARA - Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a micro-cap biotech company with a market capitalization of $1.77 million, announced Wednesday that the Japanese Patent Office has granted Patent JP 7714571B for one of the company’s pipeline assets, a modified stilbenoid compound intended to treat epilepsy and seizures.
The patent, granted on July 18, will remain in effect until March 31, 2041, providing Protagenic with exclusivity for specific compounds, formulations containing several drug candidates, and their medical applications. According to InvestingPro data, the company maintains a strong cash position with more cash than debt on its balance sheet.
"We are delighted to announce the grant of this important patent for the Company in Japan," said Colin Stott, Chief Operating Officer of Protagenic Therapeutics. The approval builds upon a previous grant of the same patent in the United Kingdom (Patent GB2609814).
The company indicated it plans to seek similar patent protection in additional territories in the future.
Japan represents the world’s third-largest pharmaceutical market, valued at more than $85 billion in 2025, according to information cited in the company’s press release. The global epilepsy drug market was valued at approximately $11.29 billion in 2024 and is projected to reach around $18.74 billion by 2034.
Protagenic Therapeutics focuses on developing novel treatments across various therapeutic areas. The information in this article is based on a company press release statement.
In other recent news, Protagenic Therapeutics, Inc. has raised $3.1 million in cash through warrant exchanges and exercises, enhancing its working capital for the development of its drug candidates. This financial boost follows the company’s merger with Phytanix Bio Inc., completed in May 2025, which created a new entity called Phytanix, Inc. The merger aims to combine Protagenic’s peptide assets with Phytanix Bio’s cannabinoid and modified stilbenoid compounds, expanding their pipeline to include six drug candidates targeting various conditions. Additionally, Protagenic Therapeutics entered into a Warrant Exchange Agreement to exchange 459,420 warrants for 367,544 shares of common stock, which will be finalized within six months. In corporate governance developments, the company appointed Timothy R. Wright as an independent director, bringing the total number of independent directors to three. These recent developments reflect Protagenic Therapeutics’ strategic efforts to bolster its financial position and expand its treatment pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.